{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:37:49Z","timestamp":1780083469852,"version":"3.54.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Invasive fungal disease (IFD) is a significant cause of morbidity and mortality in immunocompromised patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We hypothesize that galactomannan (GM), a component of fungal cell wall, as measured in bronchoalveolar lavage (BAL) might be a diagnostic adjunct in hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 568 hematologic cases undergoing diagnostic bronchoscopy because of respiratory symptoms and\/or suspected IFD between 2009 and 2013 at a tertiary care center in Switzerland were included in this prospective, observational cohort study. We compared accuracy of the BAL GM ELISA determination in predicting IFD as classified by the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group (EORTC\/MSG) definition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>BAL GM was positive in 155 cases (29.2%). According to the EORTC\/MSG criteria, IFD was classified as possible in 182 (34.3%), probable in 45 (8.5%), and proved in six (1.1%). BAL GM provided 50% sensitivity, 73.0% specificity, 16% positive predictive value, and 93% negative predictive value for diagnosing proven+probable IFD. Results were similar when antifungal treatment and radiologic suspicion of IFD were used as the gold standard. The area under the curve of the receiver operating characteristic curve for the diagnosis of proven+probable IFD was 0.716 (95% confidence interval, 0.638\u20130.794; P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GM in BAL had modest agreement with EORTC\/MSG criteria for diagnosing IFD in immunocompromised patients with a high degree of antifungal exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201403-0431oc","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T16:59:14Z","timestamp":1404925154000},"page":"309-317","source":"Crossref","is-referenced-by-count":45,"title":["Galactomannan in Bronchoalveolar Lavage for Diagnosing Invasive Fungal Disease"],"prefix":"10.1093","volume":"190","author":[{"given":"Kristina","family":"Affolter","sequence":"first","affiliation":[{"name":"Clinic of Pulmonary Medicine and Respiratory Cell Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tamm","sequence":"additional","affiliation":[{"name":"Clinic of Pulmonary Medicine and Respiratory Cell Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Jahn","sequence":"additional","affiliation":[{"name":"Clinic of Pulmonary Medicine and Respiratory Cell Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Halter","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Hospital Basel, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Hospital Basel, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[{"name":"Clinic of Pulmonary Medicine and Respiratory Cell Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"key":"2026032100254515300_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"2026032100254515300_bib2","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1111\/j.1439-0507.2010.01903.x","article-title":"Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States","volume":"54","author":"Kim","year":"2011","journal-title":"Mycoses"},{"key":"2026032100254515300_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/myc.12161","article-title":"Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study","volume":"57","author":"Candoni","year":"2014","journal-title":"Mycoses"},{"key":"2026032100254515300_bib4","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"2026032100254515300_bib5","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2026032100254515300_bib6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026032100254515300_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QCO.0b013e32832e074d","article-title":"Prevention and treatment of invasive fungal diseases in neutropenic patients","volume":"22","author":"Almyroudis","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"2026032100254515300_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1471-2334-12-237","article-title":"Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients","volume":"12","author":"Buess","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2026032100254515300_bib9","doi-asserted-by":"crossref","first-page":"e65776","DOI":"10.1371\/journal.pone.0065776","article-title":"Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model","volume":"8","author":"Schwarzinger","year":"2013","journal-title":"PLoS ONE"},{"key":"2026032100254515300_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2026032100254515300_bib11","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026032100254515300_bib12","article-title":"Update on the laboratory diagnosis of invasive fungal infections","volume":"3","author":"Posteraro","year":"2011","journal-title":"Mediterranean J Hematol Infect Dis"},{"key":"2026032100254515300_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jinf.2010.08.014","article-title":"Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"61","author":"Park","year":"2010","journal-title":"J Infect"},{"key":"2026032100254515300_bib14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026032100254515300_bib15","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromized patients","volume":"4","author":"Leeflang","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032100254515300_bib16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/444462","article-title":"Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies","volume":"41","author":"Weisser","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2026032100254515300_bib17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1378\/chest.09-0701","article-title":"Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies","volume":"137","author":"Bergeron","year":"2010","journal-title":"Chest"},{"key":"2026032100254515300_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1378\/chest.10-0488","article-title":"Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review","volume":"138","author":"Guo","year":"2010","journal-title":"Chest"},{"key":"2026032100254515300_bib19","article-title":"Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis","author":"Heng","journal-title":"Crit Rev Microbiol"},{"key":"2026032100254515300_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diagmicrobio.2010.03.017","article-title":"Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies","volume":"68","author":"Luong","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026032100254515300_bib21","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/j.ijid.2011.09.011","article-title":"Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance","volume":"15","author":"Racil","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2026032100254515300_bib22","author":"Affolter","year":"2014"},{"key":"2026032100254515300_bib23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1183\/09031936.00180808","article-title":"Propofol versus combined sedation in flexible bronchoscopy: a randomised non-inferiority trial","volume":"34","author":"Stolz","year":"2009","journal-title":"Eur Respir J"},{"key":"2026032100254515300_bib24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1378\/chest.07-0175","article-title":"BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host","volume":"132","author":"Stolz","year":"2007","journal-title":"Chest"},{"key":"2026032100254515300_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01591487","article-title":"Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis","volume":"15","author":"Sulahian","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026032100254515300_bib26","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1128\/JCM.00942-12","article-title":"Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review","volume":"50","author":"Avni","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2026032100254515300_bib27","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/429921","article-title":"Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay","volume":"40","author":"Marr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2026032100254515300_bib28","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/jac\/dks208","article-title":"Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies","volume":"67","author":"Reinwald","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026032100254515300_bib29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bbmt.2010.11.013","article-title":"Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients","volume":"17","author":"Nguyen","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026032100254515300_bib30","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/jac\/dks111","article-title":"Piperacillin\/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay","volume":"67","author":"Mikulska","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026032100254515300_bib31","author":"Donnelly"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/190\/3\/309\/67217984\/ajrccm_190_3_309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/190\/3\/309\/67217984\/ajrccm_190_3_309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:25:54Z","timestamp":1774067154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/190\/3\/309\/8505225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,8,1]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201403-0431oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,8]]},"published":{"date-parts":[[2014,8,1]]}}}